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Mutations in the Bacterial Ribosomal Protein L3 and Their
Association with Antibiotic Resistance
Rasmus N. Klitgaard,a Eleni Ntokou,a Katrine Nørgaard,a Daniel Biltoft,a Lykke H. Hansen,a Nicolai M. Trædholm,b Jacob Kongsted,b
Birte Vestera
Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense M, Denmarka; Department of Physics, Chemistry and Pharmacy, University
of Southern Denmark, Odense M, Denmarkb
Different groups of antibiotics bind to the peptidyl transferase center (PTC) in the large subunit of the bacterial ribosome. Resis-
tance to these groups of antibiotics has often been linked with mutations or methylations of the 23S rRNA. In recent years, there
has been a rise in the number of studies where mutations have been found in the ribosomal protein L3 in bacterial strains resis-
tant to PTC-targeting antibiotics but there is often no evidence that these mutations actually confer antibiotic resistance. In this
study, a plasmid exchange system was used to replace plasmid-carried wild-type genes with mutated L3 genes in a chromosomal
L3 deletion strain. In this way, the essential L3 gene is available for the bacteria while allowing replacement of the wild type with
mutated L3 genes. This enables investigation of the effect of single mutations in Escherichia coliwithout a wild-type L3 back-
ground. Ten plasmid-carried mutated L3 genes were constructed, and their effect on growth and antibiotic susceptibility was
investigated. Additionally, computational modeling of the impact of L3 mutations in E. coliwas used to assess changes in 50S
structure and antibiotic binding. All mutations are placed in the loops of L3 near the PTC. Growth data show that 9 of the 10
mutations were well accepted in E. coli, although some of them came with a fitness cost. Only one of the mutants exhibited re-
duced susceptibility to linezolid, while five exhibited reduced susceptibility to tiamulin.
During the last 10 years, mutations in the L3 ribosomal proteinhave been associated with bacterial resistance to linezolid (an
oxazolidinone) and tiamulin (a pleuromutilin). These drugs bind
to the ribosomal peptidyl transferase center (PTC), where specific
23S rRNA mutations and methylation at 2503 also cause resis-
tance to oxazolidinones and pleuromutilins (reviewed in refer-
ences 1, 2, and 3). Themain part of L3 is positioned on the surface
of the 50S ribosomal subunit, but a branched loop extends close to
the PTC (Fig. 1), the binding site for many different ribosomal
antibiotics. The first L3 resistance mutation in bacteria was de-
tected in 2003 inEscherichia coli selectedwith tiamulin, and its role
in resistance was verified by genetic evidence (4). Since then, L3
mutations have been associated with resistance to linezolid,
tiamulin or valnemulin, and anisomycin, as reviewed in reference
1. L3mutations related to antibiotic resistance have been reported
in Brachyspira spp., Staphylococcus spp., E. coli, and Mycobacte-
rium tuberculosis. Most of the studies have lacked proof that these
mutations actually cause antibiotic resistance, except a few (4–7).
It is not evident exactly which L3 mutations have a relation to
reduced antibiotic susceptibility, but only those in the part of the
L3 protein nearest to the PTC are assumed to confer a resistance
effect. Most of the known L3 mutations are found together with
other resistance determinants, mainly mutations in the domain V
region of 23S rRNA or mutations in ribosomal protein L4 and/or
the presence of the cfr ribosomal methyltransferase gene (8–11).
Themajority of the previous studies presenting L3mutations have
not provided evidence that the mutations are the resistance deter-
minant, but L3 mutations have been repeatedly reported in con-
nection with antibiotic resistance, and it is thus important to es-
tablish what effect they have.
The rplC gene encoding the L3 ribosomal protein is located in
the S10 operon from the str-spc region of the E. coli chromosome,
encoding 11 ribosomal proteins (12). The S10 operon is strongly
regulated by the L4 ribosomal protein, the product of the rplD
gene placed just downstream of the rplC gene (13, 14). Ribosomal
proteins L3, L2, and L4 are essential and indispensable compo-
nents for formation of the PTC (15, 16). These proteins are pre-
sumed tomodulate peptidyl transferase activity by stabilizing and
maintaining the conformation of rRNA at the active site (17).
Ribosome reconstitution in E. coli has demonstrated that L3 is one
of the first ribosomal proteins to be assembled onto the 23S rRNA
and that only L3 and L24 are capable of initiating assembly of the
E. coli 50S ribosomal subunit (18, 19). Knowledge of the effect of
L3 mutations in prokaryotes is limited, but various phenotypic
effects of L3 mutations have been identified in Saccharomyces
cerevisiae. Mutations in yeast equivalent to bacterial L3 mutations
affect peptidyl transferase activity, change frame-shifting effi-
ciency, thereby altering translational fidelity, and cause rapid loss
of the M1 killer virus (20). Mutations in L3 have also been shown
to affect the binding of both A-site and P-site tRNA by altering the
conformation of the PTC nucleotides (21) and have been shown
to be responsible for trichodermin resistance (22). These observa-
tions in yeast support the notion thatmutations in bacterial L3 can
provide significant phenotypic effects.
In this study,we investigated10L3mutations inE. coli that some-
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how relate to published studies of corresponding changes associ-
ated with antibiotic resistance to linezolid and tiamulin. The in-
vestigation of the L3mutations was done by construction of an L3
knockoutE. coliAS19 strainwith the essential L3 gene provided on
plasmids. The mutations were constructed in plasmid-carried L3
genes, and the L3-mutated plasmids were introduced via plasmid
exchange into the E. coli AS19 L3-minus strain, replacing the L3
wild-type (wt) plasmids by antibiotic selection. We measured the
doubling time of all mutant strains to assay the effect of the mu-
tations on growth. Also, we made a computational analysis of the
impact of L3mutations on the structure of the 23S rRNA in the E.
coli 50S ribosomal subunit, including how they affect the position-
ing of key nucleotides in the PTC and the binding of linezolid and
tiamulin. Finally, the MICs for linezolid and tiamulin were deter-
mined for each strain and compared to those determined for the
wild type to establish the effect of L3 mutations on antibiotic sus-
ceptibility.
MATERIALS AND METHODS
Bacterial strains. The E. coli TOP10 strain (Invitrogen, Carlsbad, CA,
USA) was used for transformation of ligated plasmids. The hyperperme-
able E. coli AS19 strain (23) was used for gene knockout followed by MIC
analysis because it is muchmore susceptible to antibiotics, such as tiamu-
lin, linezolid, and other PTC-targeting antibiotics, than are other E. coli
strains. E. coli AS19L3 with plasmids encoding ampicillin resistance
(Ampr) was grown in LB medium with 100 g/ml ampicillin and 40
g/ml kanamycin. E. coli AS19L3 with plasmids encoding tetracycline
resistance (Tetr) was grown in LB medium with 5 g/ml tetracycline and
5 g/ml kanamycin.
Construction of E. coli AS19L3. A ribosomal protein L3 knockout
E. coli AS19 strain was constructed to assess the effect of plasmid-carried
L3 without a wild-type L3 background. A kanamycin resistance cassette
replaced the L3 gene in the genomic S10 operon similarly to the method
described byDatsenko andWanner (24). The essential L3was provided by
induction of a plasmid-carried L3 gene on pBAD33-L3wt where the L3
gene was placed on plasmid pBAD33 (25) under the control of the arabi-
nose-inducible promoter. The PCR product for insertion of the kanamy-
cin resistance cassette was made by Phusion DNA polymerase with the
BV389krcF and BV390krcR oligonucleotide primers (Table 1) using
pKD4 (24) as the template and transformed by electroporation into
AS19/pBAD33-L3wt/pKD46. Colonies were selected on agar plates
containing 30 g/ml kanamycin, 30 g/ml chloramphenicol, and
0.2% arabinose and incubated at 37°C for 48 h. The authenticity of the
genome replacement was confirmed by PCR and sequencing.
pBAD33-L3wt was later exchanged with the pBR322 (26) derivatives
pBR322L3WT and pBR322AmpL3 (see below) where the L3 gene had
replaced the genes encoding ampicillin and tetracycline resistance, respec-
tively. Agar plates for selection of the tetracycline-resistant plasmids
contained 5 g/ml tetracycline and 5 g/ml kanamycin, and those for
selection of the ampicillin-resistant plasmids contained 30 g/ml am-
picillin and 5 g/ml kanamycin. The L3 expression in pBAD33-L3wt is
arabinose inducible, and as the pBAD33 and pBR322 derivatives con-
tain the same origin of replication and thus cannot stably coexist in the
cell, the pBAD33-L3wt can be selected away. The exchange with
pBR322L3WT was accomplished after incubation at 37°C for 16 to 18
h, while the exchange with pBR322AmpL3 additionally required incu-
bation at room temperature for approximately 72 h. The absence of
cells with pBAD33-L3wt plasmids was verified by growth on agar
plates supplemented with 20 g/ml chloramphenicol, 5 g/ml kana-
mycin, and 0.2% arabinose.
Construction of pBR322 derivatives. For construction of pBR322 de-
rivatives pBR322L3WT and pBR322AmpL3, the L3 gene was amplified
from the pBAD33-L3 vector with forward primer BV433 and reverse
primer BV434 (Table 1). The BV433 forward primer hybridized at the
start codon of the rplC gene and contained an AvrII restriction site imme-
diately upstream of the start codon. The BV434 reverse primer hybridized
at the stop codon of the rplC gene and contained an XhoI restriction site
immediately downstream of the stop codon, giving an L3 gene flanked by
sequences with restriction sites for AvrII and XhoI, respectively. Addi-
FIG 1 The ribosomal protein L3 mutations in the 50S ribosomal subunit. (A) An X-ray structure of the E. coli 50S ribosomal subunit (PDB file 3R8T, now
superseded by 4V9D), looking down the peptide exit tunnel (open circle in the middle) with 5S RNA in light green on the top. 23S RNA is shown as gray tubing
and r-proteins in light blue, except L3, which is shown as violet. At the right is a closeup of part of the PTCwith linezolid (red) bound.Nucleotides G2056, U2504,
G2576, and C2610, shown in green, have been calculated to exhibit structural changes upon L3 mutations. (B) Amino acid sequence alignment of a partial
fragment of L3 ribosomal proteins of E. coli, S. aureus, Brachyspira hyodysenteriae, and M. tuberculosis with the mutations from this study shown above the
alignment. (C) Representation of the E. coli L3 backbone in tubing marked with the positions of the mutated amino acids.
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tionally, the vector fragment from pBR322 was amplified by PCRwithout
the bla and tet genes, respectively. Primer BV429blaFwith anAvrII restric-
tion site and primer BV430blaRwith an XhoI restriction site were used to
amplify the pBR322 vector excluding the bla gene, while primer
BV431tetF with an XhoI restriction site and primer BV432tetR with an
AvrII restriction site were used for the amplification of the pBR322 vector
excluding the tet gene. The L3 product and the two linear pBR322 plas-
mids were digested with AvrII and XhoI followed by ligation and trans-
formation into the E. coli TOP10 strain.
Construction of L3-mutated plasmids. The Q148F, N149R,
136SQF138, and 136SHL138 changes were introduced into the L3 gene on
pBR322L3WT using standard overlap extension PCR (27). The L3 mutated
genes with G144D, G147R, N149S, Q150L, and T151P changes were intro-
duced in a similarway into the L3 gene on pBAD33-L3wt as described above.
Forward primers and reverse primers were used in combinationwith reverse
and forwardmutagenic primers, respectively, for each introducedmutation,
andall primers are listed inTable1.Allmutationswerefinally transferred into
the pBR322L3WTvector, by PCRaddition ofAvrII andXhoI restriction sites
at the ends of the L3 gene, followed by restriction digestion of vector
and fragments plus ligation, resulting in the following plasmids:
pBR322L3G144D, pBR322L3G147R, pBR322L3Q148F, pBR322L3N149S,
pBR322L3N149R, pBR322L3Q150L, pBR322L3T151P, pBR322L3136SQF138,
and pBR322L3136SHL138. The plasmids were transformed into E. coli
TOP10 cells and purified and finally introduced into E. coli AS19L3 by
exchange as described below. The L3 genes on the plasmids were se-
quenced with primers BV450 and BV530 (Table 1) to verify the presence
of the mutations.
Exchange of L3-mutatedplasmids into theE. coliAS19L3 strain by
antibiotic selection. pBR322 derivatives encoding tetracycline resistance
and possessing either wild-type L3 ormutated L3 genes were transformed
intoE. coliAS19L3with pBR322AmpL3 plasmids encodingwild-type L3
and ampicillin resistance. Aliquots were plated on agar plates containing 5
g/ml of tetracycline and 5 g/ml of kanamycin and incubated at 37°C
overnight. Single colonies were purified on agar plates containing identi-
cal amounts of antibiotics and incubated at 37°C overnight. The success of
the replacement by antibiotic selection was verified by transfer of single
colonies to agar plates supplemented with 100 g/ml ampicillin and 40
g/ml kanamycin to check for the absence of the pBR322AmpL3 plasmid.
Antibiotic susceptibility testing. Drug susceptibility testing was car-
ried out using 96-well microtiter plates and measuring optical density
values at 450 nm (OD450) with a Victor 3 spectrophotometer (Perkin-
Elmer) as described previously (28). Overnight cultures of strains in LB
medium were diluted to an OD450 value of 0.01, and 100 l was mixed
with 100 l of antibiotic solutions in a series with 2-fold dilution steps.
Two-fold serial dilutions of the following antimicrobial agents were test-
ed: linezolid (0.25 to 32 g/ml), tiamulin (0.6125 to 8 g/ml), and valne-
mulin (0.015 g/ml to 2 g/ml). The MIC was defined as the lowest
concentration of antibiotic at which growth of the cultures was absent
after 24 h of incubation at 37°C.
Expression of L3 by Western blotting and verification by standard
mass spectrometry. The expression of the L3 protein in the L3 wild-type
and L3 mutant strains was examined by Western blot analysis of E. coli
AS19L3 cells harboring the respective plasmids. Culture samples were
grown under aerobic conditions and harvested at an OD450 of 0.75. Sam-
TABLE 1 DNA oligonucleotide primersa
Name Sequence (5= to 3=) Application
BV389krcF CTGGGTTAATCAGGTCATTGAGCGATTGAGAGG
TTGAAACAATGATTGAACAAGATGGATTG
Construction of E. coli AS19L3
BV390krcR CTGCGCGTCTTTCAATACTAATTCCATTGCTAT
CTCCTTAGAAGAACTCGTCAAGAAGGCG
Construction of E. coli AS19L3
BV433 GGTTCCTAGGATGATTGGTTTAGTCGGT pBR322L3WT and site-directed
mutagenesis
BV434 TTAACTCGAGTTACGCCTTCACAGCTGG pBR322L3WT and site-directed
mutagenesis
BV429blaF TCATCCTAGGCCTTTTTCAATATTATTG pBR322, excluding bla
BV430blaR GTAACTCGAGGACCAAGTTTACTCATAT pBR322, excluding bla
BV431tetF TATACTCGAGGCCGGCGGCACCTCGCTA pBR322, excluding tet
BV432tetR TCATCCTAGGTGCCTGACTGCGTTAGCA pBR322, excluding tet
BV450 GCAAACAAACCACCGCTGGTAG Sequencing the L3 gene
BV530 ACGAAAGGGCCTCGTGATAC Sequencing the L3 gene
BV366G144DF GGTCCGGATTCTATCGGTCAGAACCAG Mutagenesis
BV367G144DR CTGACCGATAGAATCCGGAACGCGGTG Mutagenesis
BV364G147RF TCTATCCGTCAGAACCAGACTCCGGGC Mutagenesis
BV365G147RR AGTCTGGTTCTGACGGATAGAACCCGG Mutagenesis
BV437Q148FF GGTTCTATCGGTTTCAACCAGACTCCGGGC Mutagenesis
BV438Q148FR CGGAGTCTGGTTGAAACCGATAGAACCCGG Mutagenesis
BV358N149SF TCTATCGGTCAGAGCCAGACTCCGGGC Mutagenesis
BV359N149SR GCCCGGAGTCTGGCTCTGACCGATAGA Mutagenesis
BV435N149RF TCTATCGGTCAGAGACAGACTCCGGGCAAA Mutagenesis
BV436N149RR GCCCGGAGTCTGTCTCTGACCGATAGAACC Mutagenesis
BV360Q150LF ATCGGTCAGAACCTGACTCCGGGCAAA Mutagenesis
BV361Q150LR GCCCGGAGTCAGGTTCTGACCGATAGA Mutagenesis
BV362T151PF GGTCAGAACCAGCCTCCGGGCAAAGTG Mutagenesis
BV363T151PR GCCCGGAGGCTGGTTCTGACCGATAGA Mutagenesis
BV526136SQF138F ACTCACGGTTCCCAGTTTCACCGCGTTCCGGGT Mutagenesis
BV527136SQF138R CGGAACGCGGTGAAACTGGGAACCGTGAGTAGC Mutagenesis
BV528136SHL138F ACTCACGGTTCCCATCTGCACCGCGTTCCGGGT Mutagenesis
BV529136SHL138R CGGAACGCGGTGCAGATGGGAACCGTGAGTAGC Mutagenesis
a The mutated nucleotides in the primers used for site-directed mutagenesis are underlined; for primers BV433, BV434, BV429, BV430, BV431, and BV432, the underlined
nucleotides correspond to the restriction sites for endonucleases AvrII and XhoI.
Klitgaard et al.
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ples were dissolved in 1 SDS–dithiothreitol (DTT) loading buffer,
boiled for 5 min, and electrophoresed and separated on 12% SDS-PAGE
gels along with standard markers. The proteins were transferred onto
polyvinylidene difluoride (PVDF) membranes (GE Healthcare). Rabbit
anti-L3 primary antibody (Genscript), raised against GAKKANRVTKPE
AGC,was diluted to a concentration of 0.86g/ml, and rabbit anti-GroEL
primary antibody (Enzo) was diluted to a concentration of 0.1 g/ml.
Goat anti-rabbit IgG (H&L) horseradish peroxidase (HRP)-conjugated
secondary antibody (Genscript) was diluted to a concentration of 0.1
g/ml for the GroEL and 0.3 g/ml for the L3. Detection was done using
enhanced chemiluminescence (ECL) Western HRP substrate (Millipore
Corporation), followed by exposure and development on X-ray film.
Verification of the specificity of the detected band as L3was performed
by standardmass spectrometry. L3 expression inAS19L3/pBR322L3WT
was confirmed by excision of a band from an SDS-PAGE experiment
equivalent to the band detected by Western blotting and around a size of
22 to 23 kDa according to a marker. The proteins in the SDS-PAGE piece
were digested with trypsin, and the resulting spectrumwas analyzed using
peptide mass fingerprinting, which confirmed the L3 identity.
Determination of strain growth rates. Broth cultures of E. coli AS19L3
possessing the wild-type L3 and mutant L3 plasmids, listed in Table 2,
were diluted into fresh LBmedium to anOD450 of 0.005. The growth rates
in the exponential-growth phase were determined by growing the strains
in 50 ml LB medium at 37°C under conditions of constant shaking and
recording OD450 values every 30min for 7 to 8 h. The data were plotted in
a semilogarithmic chart, exponential regression analysis was performed
on the part showing exponential growth, doubling times were calculated
from the growth rates, and data represent averages of the results of two
independent experiments.
Computational modeling. For the computational modeling of the
effects of the L3 mutations on the 23S rRNA, an 85-Å sphere of atoms
was constructed from the E. coli 50S ribosome structure (PDB file 3OFC,
now superseded by 4V7T), centered at chloramphenicol bound in the
X-ray structure. This sphere was then prepared using the protein prepa-
ration wizard in the Schrödinger Suite (Schrödinger Release 2013-3;
Schrödinger Suite 2013 Protein Preparation Wizard) (Epik version 2.6,
Schrödinger, LLC, New York, NY, 2013; Impact version 6.1, Schrödinger,
LLC, New York, NY, 2013; Prime version 3.3, Schrödinger, LLC, New
York, NY, 2013). (i) Atom types were assigned and hydrogen atoms were
added followed by minimization using the OPLS2005 force field; (ii) zinc
and magnesium ions were kept in the model, while chloramphenicol and
water were removed; and (iii) protonation and tautomer/flip states were
determined for the protein part of the system. To take into account effects
of the solvent (although the effects were small due to the large size of the
system sphere), the Desmond program (Schrödinger Release 2013-3)
(Desmond Molecular Dynamics System v, D. E. Shaw Research, New
York, NY, 2013; Maestro-Desmond Interoperability Tools, version 3.6,
Schrödinger, New York, NY, 2013) was used to set up an orthorhombic
solvation box with a 10-Å buffer around the PTC model. The simulation
box contained approximately 575,000 water molecules, 2,000 Na ions
for neutralizing the model, and 150 mMNaCl (approximately 550 mole-
cules). Energy minimization was accomplished in a stepwise fashion, and
all atoms were minimized to a 0.5 kcal/mol convergence for the total
energy in the last minimization round.
The different L3 mutations were made using the automated procedure
implemented in Schrödinger followed by energy minimization: first by en-
ergyminimization in the local region around themutated residue (including
all residues within 6 Å of the mutated amino acid) and then by complete
energy minimization. The root mean square deviation (RMSD) calculations
for selected residues were calculated with the “rmsd_by_residue.py” script
from Schrödinger’s script database (version 2013-3). The RMSD reference
model was set up in the sameway as for themutated PTCmodels (described
above) but with the wild type. All water molecules and sodium and chloride
ionswere removed from theminimized systems. All the docking calculations
were performed using the Glide program in XP (extraprecision) mode
(Small-Molecule Drug Discovery Suite 2014-3) (Glide v, Schrödinger, LLC,
New York, NY, 2014). The 85-Å sphere described above was reduced to a
60-Å sphere because of limitations with respect to the size of the system that
can be considered in the Glide program and was then used for docking. The
Van derWaals radius scaling factor for the nonpolar atoms in the ligand was
set to 0.9, and the corresponding factor for the receptor atoms was set to 0.8.
A scaling factor of less than 1 is usually used in order to simulate receptor
flexibility. Finally, thepartial-charge cutoff valueswere0.15 for the ligandand
0.25 for the PTCmodel.
RESULTS
Construction of an E. coli L3 knockout strain with plasmid-
encoded L3 protein and replacement of wild-type L3 gene with
mutant L3 genes via plasmid exchange. As L3 ribosomal protein
(uL3 according to the newuniversal naming of ribosomal proteins
[29]) is essential for the viability of E. coli and as we sought to
investigatemutated L3 relative to the wild type, we constructed an
E. coli strain with an rplC genome knockout supplemented with a
plasmid-carried L3 gene expressing the essential L3 protein. The
hyperpermeable E. coli AS19 strain was used to monitor the effect
of the mutations as this strain is particularly sensitive to many
antibiotics (23). The L3 gene (rplC) in the genomic S10 operon
was replaced by a kanamycin resistance cassette as described by
Datsenko and Wanner (24), while the essential L3 gene was sup-
plied on a pBAD33 derivative (pBAD33-L3wt) under the control
of an arabinose-inducible promoter. Subsequently, we wanted con-
stitutively expressed ribosomal L3 protein, and pBAD33-L3wt was
therefore replaced by pBR322 derivatives. In the pBR322 derivatives,
the ampicillin resistance gene (bla) and the tetracycline resistance
gene (tet) were replaced with the L3 gene, forming plasmids
pBR322L3WT (Tetr) and pBR322AmpL3 (Ampr), respectively. The
L3geneswerepositioned so that theyused thepromoters of the genes
that they replaced and were thus constitutively expressed.
A plasmid exchange system was developed to express mutated
L3 in the E. coli AS19L3 strain by exchange of plasmids with
wild-type L3 genes with those encoding mutated L3. The ex-
changed plasmids are derivatives of pBR322 and contain the same
origin of replication and thus cannot stably coexist in the bacteria
(30). pBR322L3WT (Tetr) and pBR322AmpL3 (Ampr) were uti-
lized to introduce mutated L3 genes into the E. coli AS19L3
TABLE 2 Growth rates, antibiotic susceptibilities, and binding energies
of E. coli AS19L3 strainsa
Plasmid
Doubling
time (min)
MIC (g/ml)
Glide score
(kcal/mol)
LZD TIA LZD TIA
pBR322L3WT 24 8 1 6.1 8.6
pBR322L3G144D 130 NDb ND 4.9 7.1
pBR322L3G147R 37 4 4 6.2 7.7
pBR322L3Q148F 28 8 2 4.9 9.1
pBR322L3N149S 27 8 8 5.0 7.4
pBR322L3N149D 27 4 8 5.7 7.2
pBR322L3N149R 29 32 1 5.0 7.5
pBR322L3Q150L 32 2 8 5.1 6.8
pBR322L3T151P 31 4 4 5.6 8.7
pBR322L3136SQF138 25 4 1 4.9 8.8
pBR322L3136SHL138 25 4 1 5.1 8.5
a LZD, linezolid; TIA, tiamulin. The L3 mutant strain with G144D was eliminated from
the MIC analysis because of the large doubling time. Control strain E. coli AS19/pBR322
has a doubling time of 23 min, LZD MIC at 8 g/ml, and TIA MIC at 1 g/ml.
b ND, not determined.
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strain by swapping. As illustrated in Fig. 2, L3-mutated plasmids
with tetracycline resistancewere transformed intoE. coliAS19L3
with a wild-type L3 provided on pBR322AmpL3, encoding ampi-
cillin resistance. Exposing the cells to tetracycline creates a selec-
tion for E. coli AS19L3 cells with only L3-mutated plasmids and,
subsequently, ribosomes with only mutated L3. The substitution
of L3 wild-type plasmids with L3-mutated plasmids was verified
by the absence of colonies by plating on agar plates containing
ampicillin. The exchange was attempted using the antibiotics in
the opposite direction. Replacement of plasmids encoding tetra-
cycline resistance with plasmids encoding ampicillin resistance
failed in several attempts for unknown reasons. This issue was
previously observed and investigated (30).
Selection of specific mutations for introduction into ribo-
somal protein L3 in E. coli. Mutations in ribosomal protein L3
near the PTC have been associated with resistance to linezolid and
tiamulin in several important clinical pathogens. In order to ana-
lyze what role these amino acid mutations play in antibiotic resis-
tance or otherwise, we selected six L3 mutations from literature
studies: G144D (31), G147R (5, 6, 32) N149S (33), N149D (4),
N149R (7, 34), and Q150L (5, 6) (E. coli numbering). These mu-
tations have been discovered in either tiamulin-resistant or lin-
ezolid-resistant strains without any other known resistance deter-
minants. Some of them have been revealed to be directly involved
in the resistance, while the effect remains to be elucidated for
others as discussed below. In addition, L3 mutations in the region
corresponding to positions 136 to 139 of E. coli L3 have been
found in 23 S. epidermidis isolates with lowered susceptibility to
linezolid (8, 35–37) but always together with other resistance de-
terminants. To explore this region of L3, we made two mutants
with double amino acid changes and one deletion. Finally, we
introduced L3mutations Q148F and T151P; those twomutations
have not previously been identified, but other amino acid substi-
tutions at the same position and in the proximity have been found
(8, 38–41). Tables 3 and 4 list the mutations in L3 that have so far
been associated with resistance to linezolid and tiamulin.
FIG 2 A schematic illustration of the exchange procedure replacing plasmid-carried wild-type L3 with plasmid-carried mutated L3. Filled circles illustrate
pBR322AmpL3 (Ampr) and open circles pBR322mutatedL3 (Tetr). In the case shown, the selection was performed with tetracycline.
TABLE 3 Mutations in L3 that have been associated with linezolid resistance
L3 mutation(s) E. coli numbering Organism(s) Remark(s)a Reference(s)
F127-H146 118–138 S. aureus In vitro 32
Q136H/H146 127/138 S. aureus L4 mut 42
G137A 128 S. epidermidis 23S rRNA mut 36
G137S/H146R/V154L/M156T 128/138/146/148 S. epidermidis 23S rRNA mut, L4 mut 39
G137D/H146P/M156R 128/138/148 S. epidermidis 23S rRNA mut, L4 mut 39
G139R 129 S. aureus T, 23S rRNA mut 31
G139R/M156T 129/148 S. hominis T, 23S rRNA mut 40
S145 136 S. aureus 43
S145/H146Y 136/138 S. aureus cfr 9
H146R/M156R 138/148 S. epidermidis 23S rRNA mut, L4 mut 39
H146R/M156T 138/148 S. epidermidis T, 23S rRNA mut, L4 mut 8, 39
H146Q/V154L/A157R 138/146/149 S. epidermidis T, L4 mut 8
H146Q 138 S. epidermidis L4 mut 36
H146Q/V154L 138/146 S. epidermidis 23S rRNA mut, L4 mut 42
H146Q/V154L/A157R 138/146/149 S. epidermidis 23S rRNA mut, L4 mut 35
F147L 139 S. epidermidis cfr,L4 mut 36, 42
F147I 139 S. epidermidis, S. hominis T, 23S rRNA mut 8, 40
F147L/A157R 139/149 S. epidermidis cfr, L4 mut 37
G152D 144 S. aureus, S. haemolyticus, S. epidermidis In vitro,T,cfr,23S rRNA mut 10, 31, 32, 44
G152D/D159Y 144/151 S. epidermidis T, 23S rRNA mut 45
G152D/D159E/A160P 144/151/152 S. epidermidis T, 23S rRNA mut 46
V154L/M156T 146/148 S. epidermidis 23S rRNA mut 39
G155R 147 S. aureus In vitro 32
G155R/M169L 147/161 S. aureus In vitro 32
M156T 148 S. haemolyticus T, cfr, 23S rRNA mut 47
A157R 149 S. epidermidis 23S rRNA mut 43
S158Y/D159Y 150/151 S. epidermidis cfr 41
S158F/D159Y 150/151 S. cohnii cfr, L4 mut 41
Y158F 150 S. cohnii cfr 10
M169-G174 161–166 S. aureus cfr 9
C154R 149 M. tuberculosis In vitro,23S rRNA mut 7, 34
H155R 150 M. tuberculosis 34
a All isolates were clinical except the ones marked “In vitro,” which were in vitro-selected mutants. Selected additional information: T, treatment with linezolid; cfr, contained cfr
gene. For the potential additional resistance determinants, “23S rRNA mut” refers to mutations in 23S rRNA positions and “L4 mut” indicates L4 mutations.
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The 10 mutations are depicted in Fig. 1B and C and aligned
with the equivalent sequences from selected species. Nine of the 10
mutations were introduced into the L3 gene on plasmids by over-
lap extension PCR. Concurrently, restriction sites flanking the
coding regions to be used for cloning were introduced. The
N149DL3mutationwas obtained from a plasmid from a previous
study (4) and was transferred via PCR amplification and cloning.
All 10 L3 mutated genes were cloned into the pBR322L3WT vec-
tor–a pBR322 derivative with the coding region of the ampr gene
replaced by the coding region of the L3 ribosomal protein gene
and containing a tetr gene.
Growth rates of the L3 mutant strains. In order to assess the
impact of the introduced L3 mutations on the growth rate of the
strains, the doubling times of all L3mutant strains weremeasured
under optimal conditions, and the results are presented in Table 2.
The small difference in doubling time between AS19 (21min) and
AS19/pBR322 (23 min) might have been due to maintenance of
the plasmid copy number and expression of the ampr and tetr
genes. The doubling times for AS19/pBR322 and AS19L3/
pBR322L3WT (23 min) were identical, showing that the replace-
ment of the chromosomal expression of the L3 gene with the plas-
mid-carried wild-type L3 gene did not significantly affect the
growth of the bacteria under optimal conditions. An increased
doubling time was observed for all L3 mutant strains, but only L3
mutations G144D and G147R resulted in severe growth reduc-
tions, with doubling times at 130 min and 37 min, respectively.
The other L3 mutant strains grew relatively well, with doubling
times from 25 min to 32 min. Due to its very high doubling time,
AS19L3/pBR322L3G144D was excluded from further labora-
tory investigations.
Verification of L3 expression by Western blotting and mass
spectrometry.To verify expression and stability of themutated L3
ribosomal protein, aWestern blot analysis was performed to assay
the presence of L3 in all strains. An antibody against a 15-amino-
acid peptide present in all L3mutants and thewild typewas bound
tomembrane blots from SDS gels, with GroEL as a reference band
(data not shown). The blot shows that mutated L3 was present in
the mutants in amounts comparable to those seen with the wild-
type E. coliAS19 strain. Together with the results from the growth
analysis, the data indicate that the L3 expression levels in the mu-
tant strains were sufficient for new ribosome assembly.
To ensure the specificity of the antibody in the Western blot
analysis, standard mass spectrometry analysis was performed on
the band considered to represent L3 expressed in AS19L3/
pBR322L3WT. A band from an SDS-PAGE experiment equiva-
lent to the band detected by Western blotting was excised and
digested with trypsin, and the resulting spectrum was analyzed
using standard peptide mass fingerprinting, confirming the L3
identity.
Antibiotic susceptibilities of L3 mutant strains. The effect of
the L3 mutations on antimicrobial susceptibility was investigated
by MIC assays. Determinations of the MICs for linezolid and
tiamulinwere performed for all L3mutant strains as well as for the
wild type, except for L3 G144D, because of its long doubling time,
and the results are presented in Table 2. Only the E. coliAS19L3/
pBR322L3N149R mutant strain showed a considerably higher li-
nezolidMIC (32g/ml) than L3-wild-type strainE. coliAS19L3/
pBR322L3WT (8 g/ml). The other L3 mutants showed either
wild-type susceptibility or a slightly lower value not considered
significantly different (less than a 2-fold difference). The L3
Q150Lmutant showed higher susceptibility (2g/ml) to linezolid
than the rest of the strains, indicating moderate hypersensitivity.
Five of the nine mutants investigated showed a higher tiamulin
MIC than the wild type. The highest tiamulin MICs (8 g/ml)
were observed for the L3 mutant strains with N149S, N149D, and
Q150L. Slightly lowered tiamulin susceptibility results were ob-
served for the L3 mutant strains with G147R and T151P, with a
tiamulin MIC of 4 g/ml compared to 1 g/ml for the wild type.
All five strains also exhibited 2-fold-lower susceptibility to the
pleuromutilin valnemulin (from 0.06 g/ml for the wild type to
0.12 g/ml for the mutants; data not shown), which supports the
tiamulin data. The effects for each strain are discussed further
below.
Computational modeling of the effects of L3 mutations on
TABLE 4 Mutations in L3 that have been associated with tiamulin resistancea
L3 mutation(s) E. coli numbering Organism Remark(s) Reference(s)
R141S E. coli 6
G144R/G152D/D159Y 135/144/151 S. aureus 5
N148K 149 B. hyodysenteriae 23S rRNA mut 33
N148S 149 B. hyodysenteriae 23S rRNA mut 33, 48
N148S 149 B. pilosicoli 23S rRNA mut 33
R149S 141 S. aureus 6
N149D 149 E. coli 4
S149I 150 B. hyodysenteriae 33
S149T 150 B. hyodysenteriae Animal isolates, 23S rRNA mut 48
G152V 148 S. roseosporus 38
G152D 144 S. aureus 5
G152D/G155R 144/G147 S. aureus 5
G152D/D159Y 144/T151 S. aureus 5
G152D/G155R/D159Y 144/147/151 S. aureus 5
G153R 153 E. coli 6
G155R 147 S. aureus 5, 6
K157Q 157 E. coli 6
S158L 150 S. aureus 5, 6
D159Y 151 S. aureus 5
a All isolates were in vitro-selected mutants except the ones referred to as “animal isolates.” “23S rRNA mut” refers to mutations in 23S rRNA.
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the structure of the 50S ribosomal subunit and antibiotic bind-
ing. As the strain knockout, plasmid cloning, and mutagenesis
procedures are time-consuming, we investigatedwhether compu-
tational modeling of the L3 mutations could provide a useful and
reliable estimation of the mutational effect on antibiotic binding
and structural changes.
To investigate antibiotic binding, we used docking, employing
the XP Glide methodology, which can quantify the binding mode
and energy of binding of ligands to a receptor (49). This docking
formalism predicts a docking score, called the glide score, that
reflects how strongly a given ligand binds to the receptor, which,
in our case, was binding of antibiotics to the 50S ribosomal sub-
unit from E. coli. In addition to this docking score, a positioning of
the ligand at the binding site is predicted. As the explicit inclusion
of the whole 50S subunit in the receptor model would represent a
computational challenge, and as we expected only local changes, a
sphere of atoms around the antibiotic binding site was selected to
represent the receptor model for the calculations. Such cluster
models are extensively used within computational biology and
usually represent a good compromise between accuracy and effi-
ciency. The L3 mutations were imposed into the 50S structure,
and docking experiments were performed with linezolid and
tiamulin as ligands. The predicted glide scores are listed in Table 2
together with the MIC results. Due to the highly parameterized
nature of such calculations, the glide score should change by at
least around 1 kcal/mol to express a clearly significant effect. As
seen in Table 2, the values obtained for the modulated structures
docked with either linezolid or tiamulin are fairly similar to the
glide scores for docking based on the wild-type structure. Thus,
based solely on the docking score, no decisive conclusions can be
made at this stage.
To quantify structural changes introduced by the mutations,
we calculated the root mean square deviation (RMSD) values for
selected nucleotides and amino acids using the wild type as the
reference. The RMSD provides the average change in displace-
ment of a selection of atoms for a particular structure, correlating
it to a reference structure, which in our case is a measure of how
much the atoms within a given nucleotide or amino acid have
moved on average after introduction of the specific L3 mutations.
23S rRNA nucleotide positions 2055 to 2063, 2447 to 2455, 2497
to 2507, 2572 to 2573, 2576, 2582 to 2588, and 2606 to 2610 were
selected for investigation as they have previously been reported to
be involved in binding of tiamulin and linezolid. RMSD values
that change less than 1 Å are not generally considered significant;
nevertheless, we looked closely at all RMSD values above 0.6 Å, as
some nucleotides clearly shifted. The most interesting results are
presented in Fig. 3A. The highest RMSD values were found for
nucleotides G2056 (0.82 Å), U2504 (1.12 Å), G2576 (0.60 Å), and
C2610 (0.68 Å), and, as depicted in Fig. 1A, these positions are all
in close proximity to the part of the L3 protein where the muta-
tions are placed. There is thus in general a good correlation be-
tween nucleotide RMSDs and their distances to the L3mutations.
As the calculated structural changes are very small, the results
FIG 3 Illustration of the computational modulations. (A) A selection of structural changes uponmutationsmeasured in terms of RMSDwith respect to the wild
type. The selected nucleotides are shown on the x axis with the RMSD (Å) from all L3 mutations (color code beneath the graph) on the y axis. (B) A closeup
cutaway image of the 60-Å docking sphere from the X-ray structure of the E. coli 50S (PDBfile 3OFC)with the L3mutation R149modeled into the structure. The
nucleotides most affected (see panel A above) by the mutation are shown as green sticks together with the calculated position of linezolid (ball and stick). The
wild-type N149 is superimposed in blue. The distances from the mutated R149 amino acid to nucleotides G2056 and U2504 are shown. (C) Superposition of
U2504, G2056, and linezolid from the N149R L3 and the wild-type L3 docking structures. The curved line points to the calculated structural shift of linezolid
resulting from the presence of the mutated R149 amino acid.
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point to the accumulation of small structural changes in the 23S
rRNA leading to lower affinity for the antibiotics.
DISCUSSION
In the following, the individual L3 mutations in E. coli and their
effects are discussed and related to appropriate results in the liter-
ature. The single-amino-acid mutations appear in numerical or-
der to ease comparison with L3 mutations in other bacteria (Ta-
bles 3 and 4), while the two 136NSLS139 mutations are discussed
at the end.
The L3 G144Dmutation in E. coli is equivalent to Staphylococ-
cus L3 G152D, which has been reported in Staphylococcus aureus,
S. haemolyticus, and S. epidermidis as a possible resistance deter-
minant for both linezolid and tiamulin (see Tables 3 and 4 for
references). The G152D mutation appears to be the only modifi-
cation in some Staphylococcus strains, while other strains have
additional resistance determinants. For example, the triple L3
mutations G144R/G152D/D159Y and G152D/G155R/D159Y ap-
peared in S. aureus under conditions of exposure to tiamulin and,
for G144R/G152D/D159Y, it was verified that the increased resis-
tance was solely due to these three L3 mutations (5). All three of
the mutations G152D, G155R, and D159Y resulted in decreased
susceptibility to tiamulin in S. aureus when found alone, but in-
creased resistance was observed when they were found together,
suggesting that coupled L3 mutations give higher resistance than
single L3mutations (5). The G144Dmutation was suggested to be
the only resistance determinant in a linezolid-resistant S. aureus
isolate (31) and has been suggested to reduce oxazolidinone affin-
ity by indirect perturbation of bases G2505 and U2506 of 23S
rRNA (32). The incorporation of L3 G144D into E. coli caused a
large growth inhibition with a doubling time of 130 min, and we
therefore did not pursue the effect of this mutation further. The
inhibition is surprising, as the same mutation seems to be well
tolerated in S. aureus and is placed in a relatively well-conserved
area in L3. The mutation changed the smallest amino acid glycine
to the larger and charged aspartic acid, and this might have an
impact on the folding or the tertiary structure, seemingly inhibit-
ing either incorporation of L3 into ribosomal subunits or function
of the 50S. The RMSD values in Fig. 3A (and data not shown) do
not suggest a major structural local change from this mutation to
explain this. The mutation has been reported in several unrelated
studies in Staphylococcus spp. (5, 10, 31, 32, 44–46), and it is thus
concluded that this mutation is much better accommodated in
Staphylococcus spp. than in E. coli.
The L3 G147Rmutation in E. coli is equivalent to L3 G155R in
S. aureus, which has been related to both linezolid and tiamulin
resistance (see Tables 3 and 4 for references), andwas proven to be
a single determinant that can confer cross-resistance to these an-
tibiotics (6). In E. coli, it caused considerable growth retardation
(37 min compared to 23 min for the wt) but also a small but
significant rise in the tiamulinMIC (4g/ml compared to 1g/ml
for the wt). Although it has previously been suggested as the only
resistance determinant in a S. aureus strain with a 2-fold increase
in linezolid resistance (32), no lowered susceptibility to linezolid
was seen with G147R in E. coli (Table 2). The G147Rmutation has
been implicated in disturbing linezolid binding by disrupting
U2504 (32) and was suggested to indirectly disturb the conforma-
tion of 23S RNA G2576, affecting tiamulin binding (6). As for
G144D, it is amutation that changes the small glycine to an amino
acid with a larger side chain, which might impair the local tertiary
structure. The RMSD values suggest a minor structural local
change from this mutation on 23S RNA G2576, where mutations
are known to cause linezolid resistance. Although no reduced sus-
ceptibility to linezolid resulting from L3 G147R in E. coli was ob-
served, there was a clearly reduced tiamulinMIC. This report thus
shows that a mutation at amino acid 147 in E. coli L3 can decrease
tiamulin sensitivity as a single determinant.
The L3 Q148F mutation in E. coli has not been observed in
earlier studies, but other mutations at corresponding positions in
Staphylococcus spp. have been found. In S. haemolyticus, a L3
M156T mutation has been observed together with cfr and 23S
RNA G2576T (47), which are both well-known linezolid resis-
tance determinants. The samemutation has also been found in 13
linezolid-resistant S. epidermidis isolates (8, 39) and in two lin-
ezolid-resistant S. hominis strains (40). Also, a M156R mutation
has been found in two linezolid-resistant S. epidermidis isolates
(39). As thesemutationswere all found togetherwithmutations in
23S rRNA, their contribution to linezolid resistance is unclear.
Peculiarly, a G152Vmutation, at the position equivalent to 148 in
E. coli, has been found in a pleuromutilin-resistant Streptomyces
roseosporus strain showing increased production of daptomycin
(38). In our study, the L3 Q148F mutation showed no increased
MIC of linezolid or tiamulin, so there are no indications that this
L3 position has relevance for antibiotic resistance in E. coli. How-
ever, there was a growth inhibition (28 min compared to 23 min
for the wt), indicating that the glutamine-to-phenylalanine
change at position 148 is allowed but comes with a small cost.
L3 position N149 in E. coli is the point of L3 closest to the PTC,
supporting the notion that changes can be directly involved in
resistance to binding of antibiotics in this region. The effects of
three single mutations at L3 position N149 in E. coli were investi-
gated because the mutations have been found in various bacteria
but also to investigate the effect of different amino acid changes at
the same position in relation to antibiotic resistance. The L3
N149D in E. coli was the first of the bacterial L3 mutations to be
related to antibiotic resistance (4) but resulted in a very moderate
increase in the tiamulin MIC. The E. coli L3 N149R equivalent in
S. epidermis, A157R, has been found together with 23S RNA
G2447T, which provides linezolid resistance on its own (43).
A157R has also been found in other linezolid-resistant S. epider-
midis strains together with other L3 and L4 mutations and 23S
RNA C2534T (8, 35). In Mycobacterium tuberculosis, the corre-
sponding L3C154Rmutation provides linezolid resistance (7, 34).
Finally, the E. coli N149S mutation is equivalent to the L3 N148S
mutation observed in two Brachyspira species (33, 48) with a pos-
sible link to tiamulin resistance.
The growth inhibition (27 to 29 min compared to 23 min for
the wt) for all three N149mutations in E. coli (Table 2) shows that
the changes are allowed but comewith a small cost. 149Dand 149S
increased the tiamulin MICs from 1 g/ml to 8 g/ml, and 149R
increased the linezolid MICs from 8g/ml to 32g/ml (Table 2).
Effects seen in one species might not be equivalent to similar
changes in other species, but it is known from 23S RNAmutations
that this is often the case. Also, it is striking that the E. coli L3
N149R mutation that decreased linezolid sensitivity is the same
amino acid change as the one related to linezolid resistance in both
S. epidermidis and M. tuberculosis as mentioned above. The same
goes for the 149Smutation that decreased tiamulin sensitivity inE.
coli and has been related to tiamulin resistance in Brachyspira hyo-
dysenteriae. Also, the fact that N149S and N149D affect suscepti-
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bility to tiamulin but not susceptibility to linezolid whereas
N149R affects susceptibility to linezolid but not susceptibility to
tiamulin underscores the specificity of the effects of themutations.
The correlation betweenMICvalues and docking scores (Table
2) for the amino acid 149 mutations is not impressive but may
reflect the possibility that even small changes in binding energies
can affect the MICs. The RMSD values for N149R show a signifi-
cant effect on 23S RNA nucleotide U2504 (Fig. 3A), suggesting a
structural effect in this area. Figures 3B and C depict the compu-
tational modulation of the L3 N149R mutation in the presence of
linezolid, where the mutation changes the position of the phos-
phate group at U2504 and shows a slight effect on G2056, proba-
bly provided by the positive charge on the arginine. The structure
shows the close proximity between L3 149R, U2504, and linezolid
and subtle changes in conformations of U2504 and linezolid rel-
ative to the wild-type structure. The model supports the notion
that single amino acid changes in this area of L3 can cause small
local changes in nearby nucleotides that perturb the antibiotic
binding. Although small, the RMSD values for nucleotides U2506
and C2610 are also consistent with this view, as they are placed
very close to the antibiotic binding site as seen in Fig. 1.
L3 Q150 in E. coli corresponds to L3 S158 in S. aureus, where a
S158L mutation has been found to give reduced susceptibility to
tiamulin (5, 6). The resistance genotype was rationalized by the
mutation causing a perturbation of the conformation of U2504 as
U2504 is a key residue for tiamulin binding (6). In our study, the
E. coli L3 Q150L mutation confers resistance to tiamulin with an
8-fold increase from 1 g/ml to 8 g/ml (Table 2). We can thus
confirm the previous data and suggest that the L3Q150Lmutation
is not species specific butmay be found in various species.We find
an extended doubling time from 23 min for the wt to 32 min
(Table 2), again suggesting that the mutations come with a cost.
According to the RMSDdata, themutation does not seem to affect
U2504 or other 23S rRNA nucleotides significantly and the only
and maybe significant change in RSMD is seen for C2610.
A D159Y mutation, corresponding to position 151 in E. coli,
has been found in two S. epidermidis isolates together with cfr and
L3 mutation S158Y and has been found in one S. cohnii isolate
together with cfr, L3 mutation S158F, and additional L4 muta-
tions, all exhibiting elevated linezolidMICs (32g/ml) (41). It has
been suggested by Mendes et al. that L3 mutations S158Y and
D159Y act synergistically with cfr and somehow contribute to the
elevated linezolid MIC results (41). Also, in another study, five S.
epidermidis isolates with linezolid MICs of256 g/ml harbored
the D159Y but also 23S rRNA mutations and other L3 mutations
(45), and these other mutations might be responsible for the ele-
vatedMICs. TheD159Ymutation has also been found in S. aureus
isolates with reduced susceptibility to tiamulin, and these strains
exhibited a slight defect in growth (5). In our study, the L3 T151P
mutation in E. coli at the position corresponding to L3 position
159 in Staphylococcus spp. resulted in a reduction of the suscepti-
bility to tiamulin, with a 4-fold increase in the MIC from 1 g/ml
to 4g/ml, but no change in sensitivity to linezolid (Table 2). This
is in accordance with the tiamulin effect described above, but we
cannot support any conjecture of an influence on linezolid MICs
from thismutation. As also reported for S. aureus (5), we found an
extended doubling time, from 23 min for the wt to 31 min (Table
2), similar to what is seen for the neighboring Q150L mutation
discussed above.
A number ofmutations and a deletion have been found in L3 at
position 145SHF147 in S. epidermidis and S. aureus strains with
reduced susceptibility to linezolid (see Table 3 for details on mu-
tations and references). Except for one, they are all found together
with other L3 mutations, L4 mutations, 23S RNA mutations, or
the cfr gene. The exception is a S145 mutation from a clinical S.
aureus isolate with no report of other known resistance determi-
nants (43). The Staphylococcus L3 145SHF147 region corresponds
to 136NSLS139 in E. coli L3, which is thus one amino acid longer.
To investigate this region, we made two mutants, 136SQF138
and 136SHL138, each with both a deletion and two mutations, to
make mimics of the Staphylococcus region. L3 mutations
136SQF138 and 136SHL138 in E. coli showed only a small effect
on doubling times (25 min compared to 23 min for the wt), indi-
cating that these mutations are well tolerated. They showed no
effect on either linezolid or tiamulin susceptibility, as seen inTable
2. Also, the X-ray structure shows that the L3 136NSLS139
branched-loop area lies 20 Å away from the linezolid binding
site. There is thus no indication in our E. coli study to support a
contribution from L3mutations in this area to the observed resis-
tance in Staphylococcus spp. We cannot exclude the possibility of
such a contribution, but find itmore likely that these L3mutations
play some other role. They might somehow facilitate the presence
of the resistance determinants with which they are found. For
example, the linezolid resistance caused by a mutation at position
2576 in 23S RNA has been shown to confer a growth defect in S.
pneumoniae, but this fitness cost was rescued by a L3 mutation at
position Y137H (50). This Y137Hmutation, which did not confer
any reduced susceptibility to linezolid alone, is at the L3 position
in S. pneumoniae that corresponds to the E. coli L3 S139.
Conclusion. We have constructed an E. coli AS19L3 strain
and developed a plasmid exchange system to replace plasmid-
carried wild-type L3 genes with mutant L3 genes. This enabled us
to express mutated L3 genes on plasmids in the E. coli AS19L3
strain and thus to investigate the effect of L3 mutations without
any selective pressure under conditions comparable to those cor-
responding to similar wild-type expression. Of the 10 investigated
mutants, five exhibited decreased sensitivity to tiamulin and one
showed decreased sensitivity to linezolid. Threemutations did not
show an effect on antibiotic resistance, althoughmutations at cor-
responding positions in L3 genes in other bacteria have been re-
lated to antibiotic resistance. This is not surprising for at least
three reasons. (i) As the L3 genes from various bacteria are not
very well conserved along the whole gene, it cannot be expected
that a mutation in a specific area would exert the same effect in
different bacteria. (ii) Many of the reported L3 mutations are
found together with the well-known resistance determinants,
namely, 23S rRNA mutations and the cfr gene, and even though
they might appear for a reason, they do not necessarily have to
contribute on their own to resistance. In addition, many of the
strains harbor several L3 and L4mutations thatmay ormay not be
individually implicated to resistance. (iii) It is likely that some of
the L3 mutations that arise in antibiotic-resistant strains rescue
some detrimental effects of the other resistance determinants, as
in the example presented in reference 50. Alternatively, they
might provide some growth advantages under certain conditions
by helping the bacteria to survive and multiply and thereby pro-
vide the opportunity to obtain antibiotic resistance by some other
mechanism.
We also explored whether computational modeling could
demonstrate the effect of L3 mutations on antibiotic binding and
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on the structure of the binding pocket. If computer calculations
can make reliable predictions about mutations, this could indeed
represent a valuable tool as a supplement to the laboratory work.
The docking scores point to only small changes in the binding
energies of linezolid and tiamulin, and the span in these binding
energies is too small to make any decisive conclusions. The MIC
changes are also moderate, so we cannot conclude whether such
calculations might be useful. The RMSD values show very mod-
erate changes of the structure, but the nucleotides predicted to be
influenced are in fact those located close to the L3 mutations and
might thus reflect the actual changes. Also, no dramatic structural
effects are expected, as those would probably not be allowed in
such an important and well-conserved region as the peptidyl
transferase area.
Our “knockout plus plasmid” model has convincingly shown
that six of nine investigated L3 mutations affect antibiotic func-
tion in E. coli and that many of the mutations are relatively
well tolerated. The literature with L3 mutations point to the fact
that they are often present together with other possible resistance
determinants, so there is still a big challenge in determining the
cooperative effect of multiple players in antibiotic resistance.
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